scholarly journals MP45-16 EVIDENCE FOR A ROLE OF THE GHRELIN SYSTEM IN THE HYPERPLASTIC PROSTATE: CONNECTING THE METABOLIC SYNDROME AND LOWER URINARY TRACT SYMPTOMS SUGGESTIVE OF BPH?

2018 ◽  
Vol 199 (4S) ◽  
Author(s):  
Xiaolong Wang ◽  
Christian Gratzke ◽  
Yiming Wang ◽  
Christian Sterr ◽  
Qingfeng Yu ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
The Metabolic Syndrome ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

scholarly journals Relationship between Metabolic Syndrome and Lower Urinary Tract Symptoms: Hallym Aging Study

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Seong Ho Lee ◽  
Sang Kon Lee ◽  
Min Soo Choo ◽  
Kyung Tae Ko ◽  
Tae Young Shin ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Multivariate Logistic Regression Analysis ◽  
Cross Sectional ◽  
The Metabolic Syndrome ◽  
Urinary Tract Symptoms ◽  
Aging Study ◽  
Lower Urinary

The aim of the study was to test the hypothesis that the metabolic syndrome (MS) is linked to lower urinary tract symptoms (LUTS) in Korean men. This was a longitudinal study that used data collected from 328 men aged 50–89 years who were randomly selected among 1,520 participants in 2004. We collected information from 224 (68.3%) men among the original responders on the biological, medical, psychological, social, lifestyle, and economic factors in 2007. The prevalence of the MS was 187/328 (57.0%) in 2004 and 125/224 (55.8%) in 2007 among men, respectively. There was no significantly greater increase in the IPSS in men with the MS than in men without the MS over a 3-year period of time (2.0±9.37versus3.0±8.44,p=0.402, resp.). In the multivariate logistic regression analysis with control for age and life style factors, the risk factors for moderate/severe LUTS were age and erectile dysfunction (p<0.05). However, the presence of the MS did not increase the risk of moderate/severe LUTS (OR = 1.09, 95% CI 0.63–1.89,p=0.748). Our cross-sectional and longitudinal risk factor analyses do not support the hypothesis that the MS is linked to LUTS in Korean men.

scholarly journals The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review

2021 ◽  
Vol 10 (3) ◽  
pp. 416
Author(s):  
Giorgio Ivan Russo ◽  
Gaetano Larganà ◽  
Arcangelo Sebastianelli ◽  
Andrea Cocci ◽  
Marina Di Mauro ◽  
...  
Keyword(s):  
Systematic Review ◽  
Metabolic Syndrome ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Term Therapy ◽  
Urinary Tract Symptoms ◽  
The Impact ◽  
Lower Urinary

Previous data have shown that patients with metabolic syndrome (MetS) and lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement (BPE) could be refractory to the medical treatment. In this context, the evidence suggests a role for statin use in LUTS/BPE patients. The present systematic review aimed to evaluate the impact of statins on the treatment of men with LUTS/BPE. This review has been registered on PROSPERO (CRD42019120729). A systematic review of English-language literature was performed up to January 2020 in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA statement) criteria. Retrieved studies had to include adults with LUTS connected to BPE treated with statins drugs for metabolic syndrome. After removing duplicates, a total of 381 studies were identified by the literature search and independently screened. Of these articles, 10 fit the inclusion criteria and were further assessed for eligibility. Data from our systematic review suggest that a long-term therapy with statins, at least 6 months, is required to achieve significant impacts on prostate tissue and LUTS. Moreover, besides statins’ direct activity, the risk reduction of LUTS might be connected to the improvement of hypercholesterolemia and MetS. The role of statins for the treatment of LUTS/BPE may be beneficial; however, evidence from robust studies is not enough, and more clinical trial are required.

Sign in / Sign up

Export Citation Format

Share Document